Compare Cognizant Technology Solutions Corp (CTSH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cognizant Technology Solutions Corp vs TG Therapeutics Inc — how do they compare? Cognizant Technology Solutions Corp trades at $59.25 (market cap $27.03B), while TG Therapeutics Inc trades at $55.11 (market cap $8.16B). The key difference: Cognizant Technology Solutions Corp is far larger — about 3.3× TG Therapeutics Inc's market cap, and Cognizant Technology Solutions Corp pays a 2.2% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cognizant Technology Solutions Corp for 57 Days and TG Therapeutics Inc for 16 Days on average.
| CTSH | TGTX | |
|---|---|---|
Market Cap | $27.03B | $8.16B |
Volume | 9,883,888 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $86.70 | $59.06 |
52-Week Low | $38.73 | $26.94 |
Typical Hold Time | 57 Days | 16 Days |
Enterprise Value | $28.08B | $8.37B |
Dividend Yield | 2.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cognizant Technology Solutions (CTSH) trades at $59.20, up 3.73% today, with a bullish technical signal from moving averages and support at $56. The stock shows solid fundamentals with a P/E of 12.88, net income margin of 10.26%, and consistent earnings beats in recent quarters. Recent news highlights AI-driven initiatives and strong employer recognition, supporting positive sentiment.
CTSH presents a favorable risk-reward profile with a consensus price target of $64.25 offering ~8.5% upside. Key opportunities include AI integration and stable cash flow, while risks involve IT spending pressures and competitive threats. Analyst consensus is balanced between Buy and Hold ratings, reflecting cautious optimism amid industry headwinds.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
